1701:. Thanks for your message. I am hesitant to add the additional board memberships listed above, as it seems like resume padding. The current board memberships in the infobox, except for PathAI, are very significant, with Knowledge articles dedicated to each one. None of the boards you listed have Knowledge articles. Restricting the list to the most significant boards maintains focus on what is important and prevents the list from becoming too long, which would be a disservice to the reader. I have removed PathAI from the list.
465:. Thanks for helping out with the above edits. I have re-written the sentence for the first edit that you declined above in a way that more precisely reflects the sources supplied. Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..." "Also under his leadership, Vertex acquired Semma Therapeutics for $ 950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880. "
113:
95:
1526:
1319:
1138:
1000:
755:
684:
637:
548:
242:
64:
187:
427:
1859:
1267:
1107:
944:
599:
123:
1760:, (NICE) said in its final draft guidance that Orkambi, Symkevi, and Kaftrio are recommended for the treatment of Cystic Fibrosis, with Vertex coming to a long-term, extended, reimbursement agreement with the NHS. This final decision differs from its provisional draft guidance from November 2023 that recommended that the three drugs were
284:
Also in the Vertex section, please add the following as a new paragraph below the sentence that begins "On
October 24, 2019, Vertex reached an agreement..." "While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $ 7.74 billion at the beginning of 2012 to
1496:
I've declined this because the statements are factually correct and written in neutral tone and relate to actions that Leiden has made. Sky News certainly isn't the best of sources, but you don't seem to be contesting the factors, only their relevance to the page. It provides information about the
1033:
Please move the above sentence about
Odyssey to the end of the first paragraph in the "Boards and awards" section, directly after "Leiden is also the chairman of Casana, a home health monitoring company. The sentence fits better there since Leiden is the chairman of those boards mentioned in that
1462:
Criticism of Vertex pricing structures for
Orkambi, a groundbreaking cystic fibrosis drug costing in the region of US$ 135,000 to US$ 270,000 per patient per year depending on the patient's country, has resulting in campaigns by concerned parent groups addressed to Leiden. Leiden wrote to the UK
1896:
for your edits. I hear your suggestion to move those two paragraphs and I'd appreciate holding off on that for a bit while I am working now on updates to the "Pricing in the UK" section of the Vertex article. When that edit request is ready, I will post it and ping you. I'd appreciate your
1541:
Hello. I made some simple edits on
Jeffrey Leiden's page which I believe are not controversial in any way, mostly updating some facts, and I summarized the edits I made in the edit summary box. Let me know if I did something inappropriate. However, the following edits are perhaps less
924:. Thanks for implementing the second bullet point above. Sorry that the source for the first bullet point caused you to hesitate about using something on dropbox. I am happy for you to use the Vertex website if you feel that is a better option. Once again, thank you for your work.
1466:
However in
November 2023 the National Institute for Health and Care Excellence (NICE) recommended that three Vertex drugs, Kaftrio, Orkambi and Symkev were above the acceptable range of NHS resources in terms of cost effectiveness, despite positive outcomes for Cystic Fibrosis
261:
Please add the following sentence as a new paragraph in the correct chronological order in the Vertex section, after the sentence that begins "In 2015 Vertex shareholders..." "The 2019 acquisition of Semma
Therapeutics led to VX-880, the first potentially curative
1659:
for implementing the edit request. If its not too much trouble, can you also add the following to the
Infobox under the "Board member of" parameter or, if this is better for you, I can do these edits myself directly, just let me know if I have your permission:
1825:
1463:
Prime
Minister Theresa May in 2018, suggesting Vertex might consider reducing investment in the UK as a result of the lack of agreement between Vertex and the UK's National Health Service on the pricing of a five-year access agreement for Vertex drugs.
703:
for implementing my edit request. I have an additional board membership to be added to the "Boards and awards" section as follows: "Leiden is a member of the MIT Presidential CEO Advisory Board." The source is
1334:
Hi again. The Boards and awards section needs another update. Please change the sentence "He is also chairman of the board of the
Massachusetts Competitive Partnership" to the following:
795:
Also under his leadership, Vertex acquired Semma
Therapeutics for $ 950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for
1023:
For clarity and accuracy, please change the sentence "In May 2022 Leiden joined the Board of Directors of Odyssey Therapeutics" in the "Boards and awards" section to the following:
652:
Hello. Please remove the mention of Tmunity in the second paragraph of the Boards and awards section. Leiden no longer sits on that board. This link shows he is no longer on the
1589:
Please delete the following sentence from the Boards and awards section. It is outdated and incorrect. He is now a director of the MACP, as it says further down in this section:
1113:
The only thing I've done different is rather than a new paragraph I've added the sentance to the end of an existing one, just to try and avoid too many very short paragraphs.
1042:
While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $ 7.74 billion at the beginning of 2012 to $ 69.97 billion in April 2020.
1456:: it has little or nothing to do with Jeffrey Leiden, and adds details that are not relevant for the reader to get a good understanding of Leiden's relationship to Vertex.
563:
Hi. This is John again. Please update the Boards and awards section with the following sentence: In May 2022 Leiden joined the Board of Directors of Odyssey Therapeutics.
1938:
1433:
1715:
Hi and thanks again. I understand your reasoning for not adding the additional board memberships. Thanks for explaining it and for the edit you made. All the best.
1078:
1206:
1747:
However in November 2023 the National Institute for Health and Care Excellence (NICE) recommended that three Vertex drugs, Kaftrio, Orkambi and Symkev were
1546:
In the first sentence of the article, please add the words "physician, scientist and" right before the word "businessman" so the sentence reads as follows:
1028:
In May 2022 Leiden was appointed as Chairman of the Board of Odyssey Therapeutics, a company developing novel medicines for cancer and auto-immune disease.
31:) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or
1166:
In November 2022 Leiden was named as one of several strategic advisors for the newly launched Life Sciences Private Capital, a private equity division of
43:
1251:. This is a gentle nudge in the hope that you have the time to make the simple edits as outlined above. Thanks again for all your past and future help.
1037:
Please add the following as a new paragraph in the "Vertex" section below the sentence that begins "On October 24, 2019, Vertex reached an agreement..."
1757:
1128:
990:
232:
1795:
1019:
for your recent help with this page. I hope you can take a look at the following edits and implement them if you agree they add value to the page.
894:, I've implemented your 2nd point, but do you have a better source for the first point? I'm hestitant to link to something on dropbox. Thanks. -
419:
337:
627:
1452:
Hi. Please remove the following recently added paragraphs from the Vertex section of the Leiden Knowledge article. The added content violates
1559:
It is clear from the content in the article that Leiden is a physician and scientist and those facts should be included in the introduction.
1220:
669:
1923:
1241:
1099:
724:
674:
48:
1810:
840:
487:
308:
1614:
1338:
He is a director of the Massachusetts Competitive Partnership (MACP) and previously served as chair from January 2020 to December 2022.
352:
528:
442:
1780:
140:, a collaborative effort to create, develop and organize Knowledge's articles about people. All interested editors are invited to
275:
At the end of the sentence that begins "On October 24, 2019, Vertex reached..." please remove Scotland and Spain and replace with
1933:
1741:
Hi again. Due to a deal being reached recently between the UK's NHS and Vertex, the following update to the page should be made:
1641:
I have reviewed the sources provided above, and everything checks out. I have therefore updated the article as requested above.
884:
745:
739:
622:
141:
23:
855:
712:
502:
323:
456:
1553:
Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals…"
1943:
145:
1928:
1497:
business approaches that Leiden uses to as a CEO; for example, lobbying the Prime Minister (going over the top of NICE).
1260:
221:
1417:
197:
1299:
1281:
1122:
978:
960:
933:
915:
538:
149:
818:
705:
1948:
1570:
Casgevy was approved for use in the UK (November 2023), the United States (January 2024) and Europe, (February 2024.)
1850:
1506:
1188:
Leiden was also named one of Boston Business Journal’s Power 50 for several years, including most recently in 2022.
433:
Partially done, as the sources provided for #1 said no such thing, and I'm not sure about the reliability of #2's.
200:
require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see
1906:
1887:
1745:
In the section called "Vertex" please change the fifth paragraph by deleting the first part of the last sentence:
1724:
1710:
1693:
1650:
1402:
1875:
1867:
1486:
136:
100:
1443:
394:
788:
Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..."
75:
1453:
1207:"J.P. Morgan's new life sciences private equity arm will be hottest ticket at firm's upcoming conference"
1736:
42:. If such material is repeatedly inserted, or if you have other concerns, please report the issue to
1635:
1408:
This new information has been added to the awards section and this edit request has been answered.
1309:
380:
1902:
1846:
1720:
1689:
1631:
1532:
1482:
1439:
1423:
1398:
1325:
1295:
1256:
1237:
1144:
1095:
1006:
974:
929:
880:
761:
720:
690:
665:
643:
618:
554:
524:
415:
248:
215:
46:.If you are a subject of this article, or acting on behalf of one, and you need help, please see
32:
1684:
And also remove "Path AI" from the Infobox, as Leiden is no longer on that board. Thanks again.
1413:
1580:
Please add the following sentence below the fourth paragraph of the Boards and awards section:
1373:
903:
1563:
Please add the following sentence to the end of the second paragraph in the "Vertex" section:
1277:
1118:
956:
911:
899:
735:
205:
81:
1167:
366:
193:
715:
and implement those simple, straightforward edits that are requested there. Thanks again.
8:
841:"The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic"
488:"The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic"
309:"The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic"
63:
1898:
1842:
1811:"Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments"
1716:
1698:
1685:
1627:
1478:
1394:
1291:
1252:
1233:
1175:
In the third paragraph of the 'Boards and awards' section please replace this sentence:
1091:
970:
938:
925:
891:
876:
872:
716:
661:
614:
520:
411:
211:
1871:
1502:
1409:
290:
In the last paragraph of the Vertex section, please change April 2023 to April 2024.
257:
Hi. I am John and I would like to request some updates to Jeffrey Leiden's article.
1883:
1706:
1646:
1474:
1390:
1287:
1273:
1248:
1157:
for implementing my most recent edit request. Below are a few additional requests:
1154:
1114:
1016:
966:
952:
921:
907:
895:
868:
731:
706:
https://www.dropbox.com/s/6nfjmjqb98o9p4k/2022%20MIT%20CEO%20AB%20BRIEFING.pdf?dl=0
128:
1866:
The sources check out, so I have incorporated the above requested changes in this
1781:"Vertex Finally Reaches Pricing Deal With England's NHS for Cystic Fibrosis Drugs"
796:
452:
438:
267:
39:
1161:
Please add the following sentence to the end of the 'Boards and awards' section:
774:
Please add the following sentence to the end of the 'Boards and awards' section:
201:
1594:
He is also chairman of the board of the Massachusetts Competitive Partnership.
1917:
1498:
338:"Landmark NHS deal to open up access to life-changing cystic fibrosis drug"
1893:
1879:
1838:
1702:
1656:
1642:
847:
700:
657:
1897:
collaboration and thoughts on those upcoming suggestions. Thanks again.
1355:
1180:
Leiden was also named one of Boston Business Journal’s Power 50 in 2018.
494:
315:
1516:
610:
462:
448:
434:
224:) has been paid by Vertex Pharmaceuticals on behalf of Jeffrey Leiden.
263:
1870:. However I am wondering if the fourth and fifth paragraphs of the
148:. For instructions on how to use this banner, please refer to the
112:
94:
276:
1796:"Vertex Reaches Pricing Deal With NHS for Cystic Fibrosis Drugs"
1221:"Meet the 2022 Boston Business Journal Power 50 Movement Makers"
832:
1535:
by an editor with a conflict of interest has now been answered.
1328:
by an editor with a conflict of interest has now been answered.
1147:
by an editor with a conflict of interest has now been answered.
1009:
by an editor with a conflict of interest has now been answered.
764:
by an editor with a conflict of interest has now been answered.
693:
by an editor with a conflict of interest has now been answered.
646:
by an editor with a conflict of interest has now been answered.
579:
557:
by an editor with a conflict of interest has now been answered.
479:
300:
251:
by an editor with a conflict of interest has now been answered.
1826:"3 CFTR modulators guaranteed public reimbursement in England"
1059:
781:
Leiden is a member of the MIT Presidential CEO Advisory Board.
653:
38:
from the article and its talk page, especially if potentially
1393:. I am hoping you can help out again with this edit request.
1432:
1079:"How A Medical Brainiac CEO Turned Brilliance Into Billions"
395:"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 10-K"
1841:
who helped with the previous edit request. Thanks so much.
904:
https://www.vrtx.com/our-company/leadership/jeffrey-leiden/
330:
373:
1198:
613:
who has helped on this page in the past. Thanks so much.
1615:"CRISPR gene therapy Casgevy secures approval in Europe"
381:"Market capitalization of Vertex Pharmaceuticals (VRTX)"
359:
856:"Vertex begins human testing for diabetes cell therapy"
503:"Vertex begins human testing for diabetes cell therapy"
324:"Vertex begins human testing for diabetes cell therapy"
660:
who helped with my last edit request. Thanks so much.
447:
I am marking this request as answered, per the above.
344:
204:. For advice about reviewing paid contributions, see
1576:
This information updates the status of these drugs.
711:
I would also appreciate if you could take a look at
118:
1939:
Talk pages of subject pages with paid contributions
1772:
1758:National Institute for Health and Care Excellence
1153:Once again, I want to express my appreciation to
353:"Vertex Inks New Cystic Fibrosis Deals In Europe"
1915:
1677:Governor's Task Force on Artificial Intelligence
819:"MIT Presidential Advisory Board Annual Meeting"
1787:
1129:JP Morgan advisor and Boston Bus Journal years
991:Odyssey Therapeutics and market value increase
1223:. Boston Business Journal. 16 November 2022.
387:
1542:straightforward, so I am requesting them.
1389:Thanks so much for your help in the past,
730:The board membership was resolved below. -
1808:
1477:who has helped here in the past. Thanks,
770:I have two edits to request, as follows:
233:Edit request to update the Vertex section
1876:Vertex_Pharmaceuticals#Pricing_in_the_UK
1802:
1793:
1778:
61:
1916:
1823:
1817:
1612:
838:
628:Remove Tmunity, an outdated board post
485:
383:. Companies Market Cap. 31 March 2022.
369:. Market Cap History. 31 January 2022.
306:
1665:Massachusetts Competitive Partnership
1204:
1076:
902:) 15:21, 1 September 2022 (UTC) P.S.
350:
1520:
1427:
1313:
1132:
994:
853:
749:
746:Board position and Semma acquisition
678:
675:Additional board position and thanks
631:
542:
500:
321:
236:
181:
134:This article is within the scope of
57:
15:
1924:Biography articles of living people
1674:MIT Presidential CEO Advisory Board
1613:Barrie, Robert (13 February 2024).
80:It is of interest to the following
13:
1874:section would be better placed in
1794:Furlong, Ashleigh (20 June 2024).
14:
1960:
1824:Inácio, Patricia (26 June 2024).
1779:Manalac, Tristan (21 June 2024).
351:Bruce, Francesca (15 July 2021).
266:-based therapy for patients with
1857:
1524:
1431:
1317:
1265:
1232:Thanks again for all your help.
1136:
1105:
1077:Doler, Kathleen (16 July 2020).
998:
969:for your fast and helpful edit.
942:
753:
682:
635:
597:
546:
425:
240:
185:
121:
111:
93:
62:
21:This article must adhere to the
1606:
1366:
1348:
1213:
1070:
1052:
871:who was helpful with edits for
839:Gelman, Max (29 January 2021).
811:
572:
486:Gelman, Max (29 January 2021).
307:Gelman, Max (29 January 2021).
158:Knowledge:WikiProject Biography
1934:WikiProject Biography articles
1809:Silverman, Ed (20 June 2024).
1205:Bayer, Max (3 November 2022).
1100:18:27, 20 September 2022 (UTC)
285:$ 69.97 billion in April 2020.
161:Template:WikiProject Biography
1:
1828:. Cystic Fibrosis News Today.
1403:15:36, 21 February 2023 (UTC)
1300:15:21, 15 December 2022 (UTC)
1242:14:52, 28 November 2022 (UTC)
979:12:41, 9 September 2022 (UTC)
961:17:33, 7 September 2022 (UTC)
934:17:29, 7 September 2022 (UTC)
916:15:29, 1 September 2022 (UTC)
906:might be sufficient though? -
854:Bell, Jacob (10 March 2021).
740:17:34, 7 September 2022 (UTC)
501:Bell, Jacob (10 March 2021).
340:. EnglandNHS. 21 August 2020.
322:Bell, Jacob (10 March 2021).
24:biographies of living persons
1617:. Pharmaceutical Technology.
1282:12:06, 8 December 2022 (UTC)
1261:13:58, 5 December 2022 (UTC)
1184:With this sentence instead:
146:contribute to the discussion
7:
1944:Implemented requested edits
1907:12:35, 28 August 2024 (UTC)
1888:15:19, 20 August 2024 (UTC)
1851:13:11, 20 August 2024 (UTC)
1123:11:19, 2 October 2022 (UTC)
1060:"Odyssey Therapeutics:News"
885:13:39, 31 August 2022 (UTC)
36:must be removed immediately
10:
1965:
1929:C-Class biography articles
1487:14:59, 13 March 2024 (UTC)
875:recently. Thanks so much.
539:Addition to Boards section
1725:19:28, 30 July 2024 (UTC)
1711:20:08, 25 July 2024 (UTC)
1694:17:51, 16 July 2024 (UTC)
1651:19:22, 15 July 2024 (UTC)
1418:18:40, 4 March 2023 (UTC)
1374:"Jeffrey Leiden, MD, PhD"
725:13:24, 21 June 2022 (UTC)
670:12:32, 13 June 2022 (UTC)
457:14:36, 5 April 2022 (UTC)
443:07:45, 3 April 2022 (UTC)
420:17:43, 1 April 2022 (UTC)
410:Thank you for your help,
367:"VRTX Market Cap History"
106:
88:
1949:Declined requested edits
1636:23:12, 5 June 2024 (UTC)
1507:20:26, 20 May 2024 (UTC)
623:15:17, 19 May 2022 (UTC)
529:13:10, 16 May 2022 (UTC)
713:Talk:Reshma Kewalramani
580:"About: Our Leadership"
1756:On June 20, 2024, the
1737:Update UK pricing deal
70:This article is rated
1872:Jeffrey_Leiden#Vertex
1749:and replacing it with
1310:MACP board membership
137:WikiProject Biography
1668:Odyssey Therapeutics
1444:conflict of interest
1442:by an editor with a
1424:Vertex section edits
584:Odyssey Therapeutics
194:Wikimedia Foundation
1290:for all your help.
279:and , among others.
1655:Thank you so much
1064:odysseytx.com/news
873:Reshma Kewalramani
399:investors.vrtx.com
164:biography articles
76:content assessment
1539:
1538:
1450:
1449:
1332:
1331:
1209:. Fierce Biotech.
1151:
1150:
1013:
1012:
843:. Endpoints News.
768:
767:
697:
696:
650:
649:
561:
560:
490:. Endpoints News.
311:. Endpoints News.
255:
254:
230:
229:
180:
179:
176:
175:
172:
171:
56:
55:
1956:
1865:
1861:
1860:
1830:
1829:
1821:
1815:
1814:
1806:
1800:
1799:
1791:
1785:
1784:
1776:
1748:
1626:Thanks so much,
1619:
1618:
1610:
1528:
1527:
1521:
1435:
1428:
1382:
1381:
1370:
1364:
1363:
1360:masscompetes.org
1352:
1321:
1320:
1314:
1269:
1268:
1225:
1224:
1217:
1211:
1210:
1202:
1140:
1139:
1133:
1109:
1108:
1090:Thanks so much.
1083:
1082:
1074:
1068:
1067:
1056:
1002:
1001:
995:
950:
946:
945:
860:
859:
858:. BiopharmaDive.
851:
845:
844:
836:
830:
829:
823:
815:
799:known as VX-880.
757:
756:
750:
686:
685:
679:
654:board of Tmunity
639:
638:
632:
605:
601:
600:
588:
587:
576:
550:
549:
543:
519:Thanks so much.
507:
506:
505:. BiopharmaDive.
498:
492:
491:
483:
432:
429:
428:
403:
402:
391:
385:
384:
377:
371:
370:
363:
357:
356:
348:
342:
341:
334:
328:
327:
326:. BiopharmaDive.
319:
313:
312:
304:
244:
243:
237:
189:
188:
182:
166:
165:
162:
159:
156:
142:join the project
131:
129:Biography portal
126:
125:
124:
115:
108:
107:
97:
90:
89:
73:
67:
66:
58:
44:this noticeboard
16:
1964:
1963:
1959:
1958:
1957:
1955:
1954:
1953:
1914:
1913:
1892:Thanks so much
1858:
1856:
1835:
1834:
1833:
1822:
1818:
1807:
1803:
1792:
1788:
1777:
1773:
1746:
1739:
1624:
1623:
1622:
1611:
1607:
1525:
1519:
1426:
1387:
1386:
1385:
1372:
1371:
1367:
1354:
1353:
1349:
1318:
1312:
1266:
1230:
1229:
1228:
1219:
1218:
1214:
1203:
1199:
1137:
1131:
1106:
1088:
1087:
1086:
1075:
1071:
1058:
1057:
1053:
999:
993:
943:
941:
865:
864:
863:
852:
848:
837:
833:
828:. 23 June 2022.
821:
817:
816:
812:
797:Type 1 diabetes
754:
748:
683:
677:
636:
630:
598:
596:
593:
592:
591:
578:
577:
573:
547:
541:
512:
511:
510:
499:
495:
484:
480:
430:
426:
408:
407:
406:
393:
392:
388:
379:
378:
374:
365:
364:
360:
349:
345:
336:
335:
331:
320:
316:
305:
301:
268:type 1 diabetes
241:
235:
186:
163:
160:
157:
154:
153:
127:
122:
120:
74:on Knowledge's
71:
12:
11:
5:
1962:
1952:
1951:
1946:
1941:
1936:
1931:
1926:
1912:
1911:
1910:
1909:
1832:
1831:
1816:
1801:
1786:
1770:
1769:
1765:
1764:
1763:
1762:
1761:
1751:
1750:
1738:
1735:
1734:
1733:
1732:
1731:
1730:
1729:
1728:
1727:
1682:
1681:
1680:
1679:
1678:
1675:
1672:
1669:
1666:
1621:
1620:
1604:
1603:
1599:
1598:
1597:
1596:
1595:
1592:
1591:
1590:
1582:
1581:
1574:
1573:
1572:
1571:
1565:
1564:
1557:
1556:
1555:
1554:
1548:
1547:
1537:
1536:
1529:
1518:
1515:
1514:
1513:
1512:
1511:
1510:
1509:
1471:
1470:
1469:
1468:
1464:
1448:
1447:
1446:was declined.
1436:
1425:
1422:
1421:
1420:
1384:
1383:
1365:
1346:
1345:
1341:
1340:
1339:
1330:
1329:
1322:
1311:
1308:
1307:
1306:
1305:
1304:
1303:
1302:
1227:
1226:
1212:
1196:
1195:
1191:
1190:
1189:
1182:
1181:
1177:
1176:
1172:
1171:
1163:
1162:
1149:
1148:
1141:
1130:
1127:
1126:
1125:
1085:
1084:
1069:
1066:. 24 May 2022.
1050:
1049:
1045:
1044:
1043:
1039:
1038:
1035:
1030:
1029:
1025:
1024:
1011:
1010:
1003:
992:
989:
988:
987:
986:
985:
984:
983:
982:
981:
862:
861:
846:
831:
809:
808:
804:
803:
802:
801:
800:
790:
789:
785:
784:
783:
782:
776:
775:
766:
765:
758:
747:
744:
743:
742:
695:
694:
687:
676:
673:
648:
647:
640:
629:
626:
607:
606:
590:
589:
570:
569:
565:
559:
558:
551:
540:
537:
536:
535:
534:
533:
532:
531:
509:
508:
493:
477:
476:
472:
471:
470:
469:
468:
467:
466:
405:
404:
386:
372:
358:
343:
329:
314:
298:
297:
293:
292:
291:
287:
286:
281:
280:
272:
271:
253:
252:
245:
234:
231:
228:
227:
226:
225:
206:WP:COIRESPONSE
190:
178:
177:
174:
173:
170:
169:
167:
133:
132:
116:
104:
103:
98:
86:
85:
79:
68:
54:
53:
49:this help page
33:poorly sourced
19:
9:
6:
4:
3:
2:
1961:
1950:
1947:
1945:
1942:
1940:
1937:
1935:
1932:
1930:
1927:
1925:
1922:
1921:
1919:
1908:
1904:
1900:
1899:JohnDatVertex
1895:
1891:
1890:
1889:
1885:
1881:
1877:
1873:
1869:
1864:
1855:
1854:
1853:
1852:
1848:
1844:
1843:JohnDatVertex
1840:
1827:
1820:
1812:
1805:
1797:
1790:
1782:
1775:
1771:
1768:
1759:
1755:
1754:
1753:
1752:
1744:
1743:
1742:
1726:
1722:
1718:
1717:JohnDatVertex
1714:
1713:
1712:
1708:
1704:
1700:
1699:JohnDatVertex
1697:
1696:
1695:
1691:
1687:
1686:JohnDatVertex
1683:
1676:
1673:
1670:
1667:
1664:
1663:
1662:
1661:
1658:
1654:
1653:
1652:
1648:
1644:
1640:
1639:
1638:
1637:
1633:
1629:
1628:JohnDatVertex
1616:
1609:
1605:
1602:
1593:
1588:
1587:
1586:
1585:
1584:
1583:
1579:
1578:
1577:
1569:
1568:
1567:
1566:
1562:
1561:
1560:
1552:
1551:
1550:
1549:
1545:
1544:
1543:
1534:
1530:
1523:
1522:
1508:
1504:
1500:
1495:
1494:
1493:
1492:
1491:
1490:
1489:
1488:
1484:
1480:
1479:JohnDatVertex
1476:
1465:
1461:
1460:
1459:
1458:
1457:
1455:
1445:
1441:
1437:
1434:
1430:
1429:
1419:
1415:
1411:
1407:
1406:
1405:
1404:
1400:
1396:
1395:JohnDatVertex
1392:
1379:
1375:
1369:
1361:
1357:
1351:
1347:
1344:
1337:
1336:
1335:
1327:
1323:
1316:
1315:
1301:
1297:
1293:
1292:JohnDatVertex
1289:
1286:Thanks again
1285:
1284:
1283:
1279:
1275:
1272:
1264:
1263:
1262:
1258:
1254:
1253:JohnDatVertex
1250:
1246:
1245:
1244:
1243:
1239:
1235:
1234:JohnDatVertex
1222:
1216:
1208:
1201:
1197:
1194:
1187:
1186:
1185:
1179:
1178:
1174:
1173:
1169:
1165:
1164:
1160:
1159:
1158:
1156:
1146:
1142:
1135:
1134:
1124:
1120:
1116:
1112:
1104:
1103:
1102:
1101:
1097:
1093:
1092:JohnDatVertex
1080:
1073:
1065:
1061:
1055:
1051:
1048:
1041:
1040:
1036:
1032:
1031:
1027:
1026:
1022:
1021:
1020:
1018:
1015:Thanks again
1008:
1004:
997:
996:
980:
976:
972:
971:JohnDatVertex
968:
964:
963:
962:
958:
954:
949:
940:
939:JohnDatVertex
937:
936:
935:
931:
927:
926:JohnDatVertex
923:
919:
918:
917:
913:
909:
905:
901:
897:
893:
892:JohnDatVertex
889:
888:
887:
886:
882:
878:
877:JohnDatVertex
874:
870:
867:I am pinging
857:
850:
842:
835:
827:
820:
814:
810:
807:
798:
794:
793:
792:
791:
787:
786:
780:
779:
778:
777:
773:
772:
771:
763:
759:
752:
751:
741:
737:
733:
729:
728:
727:
726:
722:
718:
717:JohnDatVertex
714:
709:
708:on page 21.
707:
702:
692:
688:
681:
680:
672:
671:
667:
663:
662:JohnDatVertex
659:
656:I am pinging
655:
645:
641:
634:
633:
625:
624:
620:
616:
615:JohnDatVertex
612:
609:I am pinging
604:
595:
594:
585:
581:
575:
571:
568:
564:
556:
552:
545:
544:
530:
526:
522:
521:JohnDatVertex
518:
517:
516:
515:
514:
513:
504:
497:
489:
482:
478:
475:
464:
460:
459:
458:
454:
450:
446:
445:
444:
440:
436:
424:
423:
422:
421:
417:
413:
412:JohnDatVertex
400:
396:
390:
382:
376:
368:
362:
355:. Pink Sheet.
354:
347:
339:
333:
325:
318:
310:
303:
299:
296:
289:
288:
283:
282:
278:
274:
273:
269:
265:
260:
259:
258:
250:
246:
239:
238:
223:
220:
217:
213:
212:JohnDatVertex
210:
209:
207:
203:
199:
195:
191:
184:
183:
168:
151:
150:documentation
147:
143:
139:
138:
130:
119:
117:
114:
110:
109:
105:
102:
99:
96:
92:
91:
87:
83:
77:
69:
65:
60:
59:
51:
50:
45:
41:
37:
34:
30:
26:
25:
20:
18:
17:
1862:
1836:
1819:
1804:
1798:. Bloomberg.
1789:
1774:
1766:
1740:
1625:
1608:
1600:
1575:
1558:
1540:
1533:edit request
1472:
1451:
1440:edit request
1410:Go4thProsper
1388:
1377:
1368:
1359:
1350:
1342:
1333:
1326:edit request
1270:
1231:
1215:
1200:
1192:
1183:
1152:
1145:edit request
1110:
1089:
1072:
1063:
1054:
1046:
1014:
1007:edit request
947:
866:
849:
834:
825:
813:
805:
769:
762:edit request
710:
698:
691:edit request
651:
644:edit request
608:
602:
583:
574:
566:
562:
555:edit request
496:
481:
473:
409:
398:
389:
375:
361:
346:
332:
317:
302:
294:
256:
249:edit request
218:
198:Terms of Use
135:
82:WikiProjects
47:
35:
28:
22:
1783:. BioSpace.
1475:Kj cheetham
1454:WP:COATRACK
1391:Kj_cheetham
1288:Kj cheetham
1274:Kj cheetham
1249:Kj cheetham
1168:J.P. Morgan
1155:Kj_cheetham
1115:Kj cheetham
1017:Kj_cheetham
967:Kj cheetham
953:Kj cheetham
922:Kj cheetham
908:Kj cheetham
896:Kj cheetham
869:Kj cheetham
732:Kj cheetham
1918:Categories
1767:References
1601:References
1343:References
1193:References
1047:References
1034:paragraph.
806:References
567:References
474:References
295:References
1878:section.
1467:patients.
264:stem cell
155:Biography
101:Biography
40:libellous
1837:Pinging
1473:Pinging
1378:Vrtx.com
222:contribs
1813:. STAT.
1517:Updates
1499:Klbrain
965:Thanks
699:Thanks
277:Ireland
202:WP:PAID
72:C-class
1894:Boghog
1880:Boghog
1839:Boghog
1703:Boghog
1671:Casana
1657:Boghog
1643:Boghog
1356:"MACP"
701:Iztwoz
658:Iztwoz
401:. SEC.
78:scale.
1531:This
1438:This
1324:This
1143:This
1005:This
822:(PDF)
760:This
689:This
642:This
611:PK650
553:This
463:PK650
449:Z1720
435:PK650
247:This
1903:talk
1884:talk
1868:edit
1863:Done
1847:talk
1721:talk
1707:talk
1690:talk
1647:talk
1632:talk
1503:talk
1483:talk
1414:talk
1399:talk
1296:talk
1278:talk
1271:Done
1257:talk
1238:talk
1119:talk
1111:Done
1096:talk
975:talk
957:talk
948:Done
930:talk
912:talk
900:talk
881:talk
736:talk
721:talk
666:talk
619:talk
603:Done
525:talk
453:talk
439:talk
416:talk
216:talk
192:The
144:and
1247:Hi
920:Hi
890:Hi
826:MIT
461:Hi
208:.
196:'s
29:BLP
1920::
1905:)
1886:)
1849:)
1723:)
1709:)
1692:)
1649:)
1634:)
1505:)
1485:)
1416:)
1401:)
1376:.
1358:.
1298:)
1280:)
1259:)
1240:)
1121:)
1098:)
1062:.
977:)
959:)
932:)
914:)
883:)
824:.
738:)
723:)
668:)
621:)
582:.
527:)
455:)
441:)
418:)
397:.
1901:(
1882:(
1845:(
1719:(
1705:(
1688:(
1645:(
1630:(
1501:(
1481:(
1412:(
1397:(
1380:.
1362:.
1294:(
1276:(
1255:(
1236:(
1170:.
1117:(
1094:(
1081:.
973:(
955:(
951:-
928:(
910:(
898:(
879:(
734:(
719:(
664:(
617:(
586:.
523:(
451:(
437:(
431:Y
414:(
270:.
219:·
214:(
152:.
84::
52:.
27:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
